We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, u... Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform. Show more
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying...
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors...
PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00...
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1247 | -14.2237937721 | 0.8767 | 0.9942 | 0.6607 | 430775 | 0.90229506 | CS |
4 | -4.138 | -84.6216768916 | 4.89 | 6.84 | 0.6607 | 1710153 | 1.71284702 | CS |
12 | -0.528 | -41.25 | 1.28 | 9.3722 | 0.6607 | 1220061 | 3.15658442 | CS |
26 | -0.2474 | -24.7548529117 | 0.9994 | 9.3722 | 0.61 | 833734 | 2.5485637 | CS |
52 | -0.498 | -39.84 | 1.25 | 9.3722 | 0.61 | 470062 | 2.39142436 | CS |
156 | -15.608 | -95.4034229829 | 16.36 | 18.4265 | 0.61 | 242346 | 3.68409611 | CS |
260 | -19.368 | -96.2624254473 | 20.12 | 26.75 | 0.61 | 227209 | 4.32793228 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions